Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Amortization - Intangibles: 2021-2024

Historic Amortization - Intangibles for Xeris Biopharma Holdings (XERS) over the last 4 years, with Dec 2024 value amounting to $10.8 million.

  • Xeris Biopharma Holdings' Amortization - Intangibles changed negligibly% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $10.8 million for FY2024, which is negligibly% changed negligibly from last year.
  • According to the latest figures from FY2024, Xeris Biopharma Holdings' Amortization - Intangibles is $10.8 million, which was down 0.00% from $10.8 million recorded in FY2023.
  • In the past 5 years, Xeris Biopharma Holdings' Amortization - Intangibles registered a high of $10.8 million during FY2022, and its lowest value of $550,000 during FY2021.
  • For the 3-year period, Xeris Biopharma Holdings' Amortization - Intangibles averaged around $10.8 million, with its median value being $10.8 million (2024).
  • Data for Xeris Biopharma Holdings' Amortization - Intangibles shows a peak YoY soared of 1,871.45% (in 2022) over the last 5 years.
  • Over the past 4 years, Xeris Biopharma Holdings' Amortization - Intangibles (Yearly) stood at $550,000 in 2021, then surged by 1,871.45% to $10.8 million in 2022, then remained steady at $10.8 million in 2023, then remained steady at $10.8 million in 2024.